BPC-157 Dosage in the Research Literature

BPC-157 dosage in the published literature is almost entirely preclinical. The overwhelming majority of published studies use rat or mouse models. The most common dose across the rodent literature is 10 μg/kg per day via intraperitoneal injection — the dose appearing in the Sikiric group's tendon, ligament, muscle, GI, spinal cord, cardiac, and hepatic studies.^[4][5][6][7]

A key observation from multiple dose-comparison studies is equi-potency across a 1,000-fold range: 10 ng/kg produces similar outcomes to 10 μg/kg in several models, including ligament healing and wound closure.^[4][12] This equi-potency is unusual and noted in the literature as a characteristic of BPC-157's dose-response profile — it is not a dose-dependent linear relationship.

The human pilot studies have used substantially different dose forms: 10 mg intravesicular (interstitial cystitis, 2024)^[20] and 10-20 mg intravenous (safety pilot, 2025). No extrapolation between rodent μg/kg doses and human mg doses has been validated.

A 2022 pharmacokinetic study in rats and beagle dogs published in Frontiers in Pharmacology provided the most systematic PK characterization of BPC-157 to date.^[19] Key findings:

Elimination half-life: 15.2 minutes in rats (IV); 5.27 minutes in beagle dogs (IV). Half-life is substantially shorter in dogs than rats — species difference likely reflects differential hepatic metabolism.

Intramuscular bioavailability: 14-19% in rats; 45-51% in beagle dogs. The large species gap in IM bioavailability underscores why PK extrapolation across species — and especially to humans — is not yet validated.

Clearance: BPC-157 is metabolized in the liver and cleared renally. Linear pharmacokinetics were observed across all tested doses (20, 100, 500 μg/kg IM).

Plasma levels: In the two-person human IV safety pilot, plasma levels returned to baseline within 24 hours, consistent with the animal data showing rapid clearance.

The short plasma half-life (minutes) is notable given that the tissue-repair effects observed in rodent studies persist over days to weeks. This dissociation suggests that circulating BPC-157 is not the primary driver of sustained effects — receptor-level or gene-expression changes initiated at short exposure may mediate the durable outcomes.

BPC-157's gastric-protein origin confers unusual oral stability for a peptide. Research studies have confirmed activity via multiple non-parenteral routes:

Oral gavage. The colocutaneous fistula study by Klicek et al. (2008) used both intraperitoneal and peroral (drinking water) administration at 10 μg/kg and 10 ng/kg, with similar outcomes across both routes.^[11] The wound-healing review by Seiwerth et al. (2021) confirmed equi-potent oral effects across wound types.^[12]

Drinking water (continuous oral). Several Sikiric group studies use continuous dosing via drinking water — BPC-157 in the water supply — as an alternative to bolus oral gavage. This route has shown activity in ligament,^[4] GI,^[11] and spinal cord^[7] models.

GI-specific effects. For gastrointestinal applications — ulcer, fistula, mucosal protection — oral administration is expected to deliver high local concentrations at the relevant tissue, bypassing the systemic distribution question. The efficacy signal for GI-targeted effects via oral route is among the strongest in the literature.

Systemic effects via oral route. Whether oral BPC-157 achieves systemic tissue concentrations sufficient for musculoskeletal or neuroprotective effects has not been directly compared head-to-head in published literature. The equi-potency data suggests it may, but the mechanism of systemic delivery of an orally administered peptide at these doses is not fully characterized.

In the published literature, BPC-157 capsules are not studied; oral administration uses liquid gavage or drinking-water dosing.

The published rodent literature primarily uses intraperitoneal injection — a common preclinical route that does not map directly to human clinical use. The 2022 pharmacokinetic study compared IV and IM routes in rats and dogs,^[19] finding IM bioavailability of 14-19% in rats and 45-51% in dogs. The IM route is significantly less bioavailable than IV. The study did not include subcutaneous administration.

Several wound-healing studies use local or topical application — direct administration to the wound site or topical cream to skin wounds.^[12] For injury-proximal applications, route selection in the literature reflects the hypothesis that local delivery maximizes concentration at the target tissue.

Published research protocols for BPC-157 typically dissolve lyophilized (freeze-dried) peptide in bacteriostatic water at concentrations of 1-2 mg/mL. The stability notes in the literature indicate that BPC-157 is stable in bacteriostatic water for several weeks when refrigerated — consistent with its origin protein's stability in the gastric acid environment.

Lyophilization is the standard preservation method: the peptide is freeze-dried to a powder for storage and reconstituted in sterile or bacteriostatic water before use in research protocols. This information reflects standard laboratory practice as documented in published methodology sections.

In rodent musculoskeletal studies — tendon, ligament, and muscle repair — measurable acceleration of tissue healing has been observed within 7-14 days of daily dosing. The ligament study measured improvements at multiple timepoints from day 7 through day 90;^[4] the muscle studies measured complete reversal of impaired healing by day 14.^[6]

In neurological models, the timeline is shorter. The hippocampal ischemia-reperfusion study observed full functional recovery within 24-72 hours of a single local application in rats.^[8] The spinal cord compression model showed progressive recovery from day 4 onward with full recovery by day 7 in treated animals, versus persistent deficits in controls.^[7]

No validated human timeline data exists. The human pilot studies do not report time-to-effect with the granularity available in the rodent literature.